Catalyst Pharmaceuticals, Inc. $CPRX Shares Purchased by Renaissance Group LLC

Renaissance Group LLC raised its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 8.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 356,022 shares of the biopharmaceutical company’s stock after purchasing an additional 26,965 shares during the quarter. Renaissance Group LLC’s holdings in Catalyst Pharmaceuticals were worth $7,014,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Huntington National Bank raised its position in shares of Catalyst Pharmaceuticals by 105.0% during the 2nd quarter. Huntington National Bank now owns 1,433 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 734 shares during the period. Bessemer Group Inc. raised its position in Catalyst Pharmaceuticals by 331.4% in the third quarter. Bessemer Group Inc. now owns 3,486 shares of the biopharmaceutical company’s stock valued at $69,000 after purchasing an additional 2,678 shares during the period. Jones Financial Companies Lllp raised its position in Catalyst Pharmaceuticals by 14.0% in the third quarter. Jones Financial Companies Lllp now owns 4,061 shares of the biopharmaceutical company’s stock valued at $79,000 after purchasing an additional 498 shares during the period. Dakota Community Bank & Trust NA acquired a new position in shares of Catalyst Pharmaceuticals in the 2nd quarter valued at $81,000. Finally, Vinva Investment Management Ltd purchased a new position in shares of Catalyst Pharmaceuticals during the 2nd quarter worth $206,000. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Carmen Jeffrey Del sold 10,983 shares of the firm’s stock in a transaction that occurred on Wednesday, November 26th. The shares were sold at an average price of $23.33, for a total transaction of $256,233.39. Following the sale, the insider owned 3,962 shares of the company’s stock, valued at approximately $92,433.46. This trade represents a 73.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Molly Harper sold 26,746 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $23.25, for a total transaction of $621,844.50. Following the sale, the director owned 2,360 shares of the company’s stock, valued at $54,870. This represents a 91.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 10.40% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Sunday, November 16th. Citigroup upped their price target on Catalyst Pharmaceuticals from $31.00 to $33.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Oppenheimer reaffirmed an “outperform” rating and issued a $33.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, November 7th. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research note on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Catalyst Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $33.20.

Catalyst Pharmaceuticals Price Performance

Catalyst Pharmaceuticals stock opened at $24.44 on Friday. The stock has a market cap of $3.00 billion, a PE ratio of 14.21, a P/E/G ratio of 0.82 and a beta of 0.74. The stock’s fifty day moving average is $23.59 and its two-hundred day moving average is $21.87. Catalyst Pharmaceuticals, Inc. has a 1-year low of $19.05 and a 1-year high of $26.58.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.50 by $0.18. Catalyst Pharmaceuticals had a return on equity of 39.24% and a net margin of 37.63%.The business had revenue of $148.39 million during the quarter, compared to analysts’ expectations of $136.79 million. On average, research analysts expect that Catalyst Pharmaceuticals, Inc. will post 1.9 earnings per share for the current fiscal year.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).